CN117510562B - Synthesis method of medical intermediate 2' -O-propynyl-uridine - Google Patents

Synthesis method of medical intermediate 2' -O-propynyl-uridine Download PDF

Info

Publication number
CN117510562B
CN117510562B CN202410023958.6A CN202410023958A CN117510562B CN 117510562 B CN117510562 B CN 117510562B CN 202410023958 A CN202410023958 A CN 202410023958A CN 117510562 B CN117510562 B CN 117510562B
Authority
CN
China
Prior art keywords
uridine
propynyl
reaction
propynyloxy
silane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202410023958.6A
Other languages
Chinese (zh)
Other versions
CN117510562A (en
Inventor
苗茹
陶鹏
朱海生
陆阳
陆林海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Novikon Biotechnology Co ltd
Original Assignee
Suzhou Novikon Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Novikon Biotechnology Co ltd filed Critical Suzhou Novikon Biotechnology Co ltd
Priority to CN202410023958.6A priority Critical patent/CN117510562B/en
Publication of CN117510562A publication Critical patent/CN117510562A/en
Application granted granted Critical
Publication of CN117510562B publication Critical patent/CN117510562B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)

Abstract

The application relates to a method for synthesizing a medical intermediate 2' -O-propynyl-uridine, which adopts 2,2' -dehydrated uridine as a substrate and converts the substrate into 2' -O-propynyl-uridine through the participation of other components such as propynyloxy silane and the like in a reaction. In the synthetic technical route of the application, isomers can not be generated, the purification time is shortened, the cost is reduced, and the synthesis process does not involve controlled reagents, thereby being beneficial to industrialized production.

Description

Synthesis method of medical intermediate 2' -O-propynyl-uridine
Technical Field
The invention belongs to the technical field of nucleotide synthesis, and particularly relates to a synthesis method of a medicine intermediate 2' -O-propynyl-uridine.
Background
Oligonucleotides have broad application prospects in cancer treatment and genetics, such as: an oligonucleotide is a short single stranded DNA or RNA, typically consisting of several to tens of nucleotides. They can bind to complementary DNA or RNA sequences to form stable double stranded structures, and in particular, oligonucleotides can cross-link to internal or terminal positions of DNA or RNA within a cell, which cross-link can prevent replication of the cell. Thus, the oligonucleotide can be used as a specific drug that binds to DNA or RNA of cancer cells, preventing the replication of cancer cells, and thus killing cancer cells. This method of treatment is called gene-targeted therapy because it is directed to specific gene mutations, not to all healthy or diseased cells.
In genetics, oligonucleotides are used as probes for studying the structure and function of DNA and RNA. They can also be used for gene therapy, i.e. for the treatment of genetic diseases by modification of DNA or RNA sequences. In this process, the oligonucleotides may be designed to bind to abnormal gene sequences, thereby preventing the expression of the deleterious genes.
RNAi is a common gene expression control mechanism in organisms that can inhibit the expression of a specific gene by degrading the target RNA. During RNAi, double-stranded RNA (dsRNA) is a key effector molecule that can be cleaved by the intracellular RNaseIII enzyme into small fragments, which are called siRNAs (small interfering RNAs). The siRNA can bind to the target RNA, resulting in degradation of the target RNA, thereby inhibiting expression of a particular gene.
The 2' position is an important modification site during the synthesis of siRNA. At this position, the physicochemical properties and functions of the siRNA can be altered by the addition of chemical groups (e.g., methyl, ethyl, etc.). These modifications can increase the stability and specificity of the siRNA, allowing it to bind more efficiently to the target RNA, thereby more effectively inhibiting expression of a particular gene. Wherein: sugar-modified oligonucleotides are very important substances that alter the physicochemical properties and functions of siRNA, such as: the sugar-modified oligonucleotide can activate a subsequence of the 2' -deoxy-erythro-pentofuranosyl nucleoside of RNaseH, thereby promoting degradation of the target nucleic acid.
Thus, it is important to synthesize sugar-modified oligonucleotides, 2' -O-propynyl being an organic chemical group, typically bound to the sugar moiety of the nucleotide, the presence of which can alter the chemical nature and biological activity of the nucleotide. 2 '-O-propynyl-uridine is also an intermediate for synthesizing sugar-modified oligonucleotides as a pharmaceutical intermediate containing 2' -O-propynyl, and its synthesis has received much attention.
Disclosure of Invention
In order to solve the problems, the application provides a new idea for synthesizing a medicine intermediate 2' -O-propynyl-uridine.
In order to achieve the above object, the present application is realized by the following scheme:
the application provides a method for synthesizing a medicine intermediate 2' -O-propynyl-uridine, which comprises the following steps:
Adding 2,2 '-dehydrated uridine into a reaction vessel at the temperature of minus 5 ℃ to 5 ℃, continuously introducing inert gas into the reaction vessel, continuously adding an organic solvent and propynyloxy silane into the reaction vessel under the protection of the inert gas, fully stirring for reaction, slowly dropwise adding boron trifluoride diethyl ether into the reaction vessel at the temperature of minus 5 ℃ to 5 ℃, fully stirring at the temperature of minus 5 ℃ to 5 ℃, heating the reaction vessel to 115 ℃ to 125 ℃, stirring for reaction at the temperature of 115 ℃ to 125 ℃, and sequentially carrying out reduced pressure concentration, column chromatography purification and reduced pressure concentration after the reaction is completed, thereby obtaining 2' -O-propynyl-uridine.
As a further improvement of the present application, the inert gas may be, but is not limited to, any one of nitrogen, neon, helium, argon, and the like.
As a further improvement of the present application, the propynyloxy silane is t-butyldimethyl (2-propynyloxy) silane or propynyloxy trimethylsilane.
As a further improvement of the application, the molar ratio of the 2,2' -anhydrouridine to the tert-butyldimethyl (2-propynyloxy) silane is 1:4-1:6; the molar ratio of the 2,2' -dehydrated uridine to the propynyloxy trimethylsilane is 1:4-1:6.
As a further improvement of the present application, the molar volume ratio of the 2,2' -anhydrouridine to the organic solvent ranges from 0.5mol/L to 1.5mol/L.
As a further improvement of the present application, the organic solvent is any one of N, N-dimethylacetamide and dimethylsulfoxide.
As a further improvement of the application, the molar ratio of the boron trifluoride diethyl etherate to the 2,2' -anhydrouridine is 1:2-1:3.
As a further improvement of the application, the eluent applied to the column chromatography purification is a mixed solution of dichloromethane and methanol, and the mixed solution also contains triethylamine with the volume percent of 5 percent.
As a further improvement of the application, in the mixed solution, the volume ratio of the dichloromethane to the methanol is 10:1-20:1.
As a further improvement of the application, the reaction progress is controlled by HPLC under the temperature condition of 115-125 ℃.
As a further improvement of the application, the time of the fully stirred reaction at the temperature of minus 5 ℃ to 5 ℃ is a first preset time period, and the first preset time period can be set according to the addition amount of 2,2' -anhydrouridine, propynyloxy silane and boron trifluoride diethyl ether, and can be, but not limited to, 5min to 1h, and can be, but not limited to, 10min, 20min, 30min, 50min, 1h and the like; the time for fully stirring the mixture at the temperature of 115-125 ℃ is a second preset time period, and the second preset time period can be set according to the addition amount of 2,2' -anhydrouridine, propynyloxy silane and boron trifluoride diethyl ether, and can be 1-10 h, specifically but not limited to 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h and the like.
The application has the beneficial effects that the technical route for synthesizing the 2' -O-propynyl-uridine has the following advantages:
1) Avoiding the generation of isomers and improving the purity and quality of the product.
2) The purification steps are reduced, the production cost is reduced, and the production efficiency is improved.
3) And in the synthesis process, no control reagent is used, so that the method is beneficial to industrial production and application.
4) The whole process is reasonable in design, suitable for large-scale production, and high in practicality and economy.
5) Reduces the energy consumption and the environmental pollution, and meets the requirement of sustainable development.
In conclusion, the synthetic technology route of the application has excellent economic benefit and industrial application prospect, and has positive promotion effect on the development of the related fields.
Drawings
FIG. 1 is a nuclear magnetic resonance spectrum of 2' -O-propynyl-uridine prepared in example 1;
FIG. 2 is an HPLC chart of 2' -O-propynyl-uridine prepared in example 1.
Detailed Description
In order to make the objects, technical solutions and advantages of the present application more apparent, the technical solutions of the present application will be clearly and completely described below with reference to specific embodiments of the present application and the accompanying drawings. It should be apparent that the described embodiments are only some embodiments of the present application and not all embodiments are not intended to limit the scope of the present application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application.
In order to solve the technical problems, the application provides a new idea for synthesizing 2' -O-propynyl-uridine, which has the following technical scheme:
The specific synthesis steps of 2' -O-propynyl-uridine are as follows:
Adding 0.442-0.446 mol (100-101 g) of 2,2' -dehydrated uridine (compound 6) into a reaction vessel at the temperature of minus 5 ℃ to 5 ℃ under the protection of nitrogen, sequentially adding 400-450 ml of N, N-Dimethylacetamide (DMAC), 2.20-2.23 mol (375-380 g) of tert-butyldimethyl (2-propynyloxy) silane (compound 7) or 2.20-2.23 mol (382-387 g) of propynyloxy trimethyl silane (compound 7) into the reaction vessel under the protection of nitrogen, fully stirring and reacting, then sucking 1.102-1.11 mol (156.5-157.5 g) of boron trifluoride diethyl ether (compound 8) by a 50ml registry at the temperature of minus 5 ℃ to 5 ℃, dropwise adding boron trifluoride diethyl ether which is a boron trifluoride diethyl ether complex into the reaction vessel, stirring the boron trifluoride diethyl ether for 2-4 h at the temperature of minus 5 ℃ to 15 ℃ to 125 ℃ for 125-115 minutes, and stirring and reacting for 16-115 h at the temperature of minus 15 ℃ to 115 minutes. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, purified by column chromatography and concentrated under reduced pressure to give 0.36mol (101.7 g) of 2 '-O-propynyl-uridine (compound 9) as a white solid product in a yield of 81.5% based on t-butyldimethyl (2-propynyloxy) silane or 0.33mol (93.8 g) of 2' -O-propynyl-uridine (compound 9) as a white solid product in a yield of 75.2% based on propynyloxy trimethylsilane. Wherein: in the process of column chromatography purification, the eluent is a mixed solution of dichloromethane and methanol, the mixed solution also contains 5% of triethylamine, the eluent can be added at one time or can be added for a plurality of times for washing in the process of elution, and the volume ratio of the dichloromethane to the methanol is reduced in gradient according to the addition sequence, for example: the volume ratio of dichloromethane to methanol can be reduced in a gradient way from 20:1 to 10:1, and the specific steps are as follows: if three eluents are adopted, the volume ratio of the methylene dichloride to the methanol is 20:1 for the first time, the volume ratio of the methylene dichloride to the methanol is 15:1 for the second time, and the volume ratio of the methylene dichloride to the methanol is 10:1 for the third time.
Wherein: the main reaction mechanism of compounds 6 to 9 is the following formula i:
Formula I.
Under the action of Lewis acid BF3, the carbon at the 2 'position is in an electron-deficient state, so that the compound 6 reacts with an oxygen atom of alkyl (2-propynyloxy) silane to generate S N2, and a steric hindrance effect is beneficial to generating a steric structure with a hydroxyl at the 3' position. The reaction was then quenched with methanol to give compound 9. In the reaction of the second step: 2,2' -anhydrouridine is used as a source for providing uridine moieties; the boron trifluoride part in the boron trifluoride diethyl etherate provides Lewis acid catalytic activity, and the diethyl etherate has the function of complexing the lone pair electron of ether linkage oxygen with electron-deficient boron of the boron trifluoride, so that the boron trifluoride is more stable and is favorable for canning and transportation as a commodity; n, N-dimethylacetamide provides a suitable solvent environment that allows the substrate and catalyst to interact effectively; the oxygen of propynyloxy has a pair of lone electrons, has higher reactivity, and reacts with SN2 of carbon atom in electron-deficient state at the 2' position in substrate molecule, thereby forming new chemical bond. The feeding process is easy to instantaneously release heat, so that the reaction system becomes mixed, and the temperature of-5 ℃ to 5 ℃ is set in the feeding and uniformly mixing process, so that the stability of the reaction system is maintained, and the occurrence of side reactions is controlled. The temperature of 115-125 ℃ is set to promote the reaction, break the initial combination of 2,2' -anhydrouridine and propynyloxy, and require a certain amount of energy which can be supplied by high temperature to further make them more susceptible to reaction with other molecules or groups. In addition, the high temperature may also help to increase the fluidity of the system, enabling better mixing and contacting of the substrate and reagents, thereby facilitating the progress of the reaction.
The technical route for synthesizing the 2' -O-propynyl-uridine is shown as the following formula II:
Formula II.
The 2,2' -anhydrouridine (compound 6) in the above technical scheme can be purchased from the market, and can also be prepared by the following steps:
410-414.1 mmol (100-101 g) of uridine (compound 11) is dissolved in 400-450 mL of N, N-dimethylformamide, after the uridine (compound 11) is fully dissolved, 447.2-451.9 mmol (96-97 g) of diphenyl carbonate (compound 12) and 7.82-8.42 mmol (0.65-0.7 g) of sodium bicarbonate are added, the mixture is heated to 115-125 ℃ for reaction for 8-10 hours, the reaction progress of the experiment is controlled by HPLC, after the reaction is completed, the temperature of the reaction is reduced to 20-30 ℃, and solids are separated out and filtered, thus obtaining a solid filter cake. 400-500 mL of methanol and the solid filter cake are mixed together at 20-30 ℃, stirred for 2-3 hours, and filtered again to sufficiently remove impurities and ions in the filter cake, thereby obtaining 88.2g of white powdery product (compound 6) with a yield of 95.2%.
The main reaction mechanism of compounds 11 to 6 is the following reaction mechanism formula iii:
Formula III.
After the basic sodium bicarbonate neutralizes the hydrogen ions on the nitrogen in compound 11, the electrons of compound 11 migrate to the carbonyl oxygen, then the oxygen with the negative nucleus attacks the carbon at the 2' position, then the electrons migrate to the hydroxyl oxygen at the 2' position, dehydroxylation becomes 2,2' -anhydrouridine (compound 6), and the dehydroxylated hydroxyl attacks the carbonyl of diphenyl carbonate (compound 12), which breaks down into phenol and monophenyl carbonate anions. In the reaction of the first step: uridine serves as a substrate for the reaction, providing the structure of the uridine moiety; sodium bicarbonate is used as an acid binding agent to help maintain a proper pH value so as to promote the reaction; diphenyl carbonate is used as a dehydrating agent and can react with the removed hydroxyl, so that the reaction is promoted; n, N-dimethylformamide is used as a solvent to help maintain the substrate and catalyst in a dissolved state to promote the reaction. The temperature of 115-125 ℃ is set to promote the reaction, break the initial bond of uridine, diphenyl carbonate and the like, and a certain amount of energy is required, and the energy can be provided at a high temperature. In addition, the high temperature may also help to increase the fluidity of the system, enabling better mixing and contacting of the substrate and reagents, thereby facilitating the progress of the reaction.
The technical route of the above compounds 11 to 6 is as follows formula IV:
formula IV.
To verify that the technical scheme of the present application has excellent effects, the following examples and comparative examples are also provided.
Example 1
The specific synthesis steps of 2' -O-propynyl-uridine are as follows:
0.442mol (100 g) of 2,2' -anhydrouridine (compound 6) was added to a reaction vessel at 0℃under nitrogen protection, 400ml of N, N-Dimethylacetamide (DMAC), 2.21mol (377 g) of t-butyldimethyl (2-propynyloxy) silane (compound 7) or 2.21mol (384 g) of propynyloxy trimethyl silane (compound 7) were sequentially added to the reaction vessel under nitrogen protection, the reaction vessel was stirred sufficiently, 1.105mol (156.9 g) of boron trifluoride diethyl ether (compound 8) was then sucked up with a 50ml register at 0℃and dropwise added thereto, the boron trifluoride diethyl ether here means boron trifluoride diethyl ether complex, the mass percentage of boron trifluoride was 47%, the time of dropwise addition was 3 hours, and after completion of dropwise addition, the reaction vessel was stirred at 0℃for 25 minutes, and then stirred at 120℃for 15 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, purified by column chromatography and concentrated under reduced pressure to give 0.36mol (101.7 g) of 2 '-O-propynyl-uridine (compound 9) as a white solid product in a yield of 81.5% based on t-butyldimethyl (2-propynyloxy) silane or 0.33mol (93.8 g) of 2' -O-propynyl-uridine (compound 9) as a white solid product in a yield of 75.2% based on propynyloxy trimethylsilane. Wherein: in the column chromatography purification process, the eluent is a mixed solution of dichloromethane and methanol, the mixed solution also contains 5% of triethylamine, the elution process adopts a mode of three eluents, the volume ratio of the dichloromethane to the methanol is 20:1 in the first time, the volume ratio of the dichloromethane to the methanol is 15:1 in the second time, and the volume ratio of the dichloromethane to the methanol is 10:1 in the third time.
The spectrum of 1H NMR analysis for 2' -O-propynyl-uridine (Compound 9) prepared in the present example is shown in FIG. 1, and is specifically as follows:
1H NMR (400 MHz, DMSO-d6): 11.34 (s, 1H), 7.91-7.93 (d, 2H), 5.87-5.88 (m, 1H), 5.64-5.67 (m, 1H), 5.23-5.24 (d, 1H), 5.15-5.17 (t, 1H), 4.20-4.33 (m, 2H), 4.08-4.15 (m, 2H), 3.86-3.89 (q, 1H), 3.53-3.66 (m, 2H), 3.42-3.43 (t, 1H).
the HPLC purity analysis spectrum of the 2' -O-propynyl-uridine prepared in the present example is shown in FIG. 2, and the HPLC purity is more than 95%.
Example 2
This example differs from example 1 in that 2,2 '-anhydrouridine (compound 6) of example 1 is purchased commercially, and 2,2' -anhydrouridine (compound 6) is prepared by the following steps:
410mmol (100 g) of uridine (compound 11) was dissolved in 400mL of N, N-dimethylformamide, after complete dissolution, 450mmol (96.6 g) of diphenyl carbonate (compound 12) and 8.18mmol (0.68 g) of sodium hydrogencarbonate were added, heated to 120℃and reacted for 9 hours, the progress of the above-mentioned experiment was controlled by HPLC, after completion of the reaction, the temperature of the above-mentioned reaction was lowered to 25℃and solids were precipitated and filtered to obtain a solid cake. 450mL of methanol and the above solid cake were mixed together at 25℃and stirred for 2.5 hours, and filtered again to sufficiently remove impurities and ions in the cake, to give 88.2g of a white powdery product (Compound 6) in a yield of 95.2%.
The yield of 2 '-O-propynyl-uridine (compound 9) prepared using 2,2' -anhydrouridine (compound 6) of the present example was 80%.
The sources of part of the raw materials used in examples 1 and 2 above were as follows: the 2,2' -dehydrated uridine was selected from the products of Ikkan biological medicine development Co., ltd, lot number of MPC42-1569533-2, N, N-dimethylacetamide was selected from the products of Shanghai Teitatan technology Co., ltd, t-butyldimethyl (2-propynyloxy) silane was selected from the products of Ikkan biological medicine development Co., ltd, lot number of AZF23-1159477-1, propynyloxy trimethylsilane was selected from the products of Ikkan Tekkan technology Co., ltd, lot number of RDR OWEE, boron trifluoride diethyl ether was selected from the products of Ikkan technology Co., ltd, lot number of OFPQR XE, methylene chloride was selected from the products of No. 20230308, methyl chloride was selected from the products of No. lake chemical Co., ltd, white place of Ikkan chemical Co., ltd was selected from the products of AZF23-1159477-1, and sodium bicarbonate was selected from the products of Ikkan chemical Co., ltd, sodium bicarbonate was selected from the products of No. 3790, and sodium bicarbonate was selected from the products of Ukkan chemical Co., ltd, and sodium bicarbonate was selected from the products of No. 2637042.
Comparative example 1
In order to demonstrate that the technical scheme of the present application has excellent technical effects, the preparation method reported in technical scheme reference （Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosides,Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 23, p. 5349 – 5352; or ;A Click Chemistry Approach to Pleuromutilin Conjugates with Nucleosides or Acyclic Nucleoside Derivatives and Their Binding to the Bacterial Ribosome,Journal of Medicinal Chemistry, 2008, vol. 51, # 16, p. 4957 - 4967） for preparing 2' -O-propynyl-uridine adopted in the prior art is provided as follows formula v:
Formula V.
As is clear from the technical route, the raw material adopted in the comparative example 1 is uridine, and the added auxiliary materials comprise 1, 3-dichloro-1, 3-tetraisopropyl disiloxane, bromopropyne, tetrabutylammonium fluoride and the like, and the final yield is 27.6%.
Comparative example 2
In order to prove that the technical scheme of the application has excellent technical effects, the technical scheme adopted in the prior art for preparing the 2' -O-propynyl-uridine comprises the following steps:
Step one: to 4L of methanol were added 0.409mol (100 g) of uridine (compound 1) and 0.409mol (101.93 g) of dibutyltin oxide (compound 4), heated under reflux overnight, concentrated under reduced pressure, and dried at room temperature under high vacuum overnight to give compound 5 (184.6 g, yield 95%) as a white solid.
Step two: 32.6mmol (15.5 g) of 2',3' -0- (dibutyltin base) uridine (compound 5) in the first step was added to 200mL of N, N-Dimethylformamide (DMF), and further 5.8 mL (65.2 mmol) of bromopropyne was added, and the reaction was stirred at 100℃for 6 hours, after completion of the reaction, concentrated under reduced pressure, and purified by column chromatography to give a mixed solid of 2 '-O-propynyl-uridine (compound 9) and 3' -O-propynyl-uridine (compound 10), wherein: the mass of 2' -O-propynyl-uridine was 5.7g, which was about 60% of the mixed solids, i.e., the yield was 60%. The eluent used in the column chromatography purification process is a mixed solvent of dichloromethane and methanol, and the volume ratio of the dichloromethane to the methanol is 7:1.
The technical route for synthesizing 2' -O-propynyl-uridine of the present comparative example 2 is shown in the following formula VI:
And the formula VI.
In summary, the existing technical route for synthesizing 2' -O-propynyl-uridine comprises the following steps: 1) The synthetic technology route in comparative example 1 is long, three steps of reaction are needed, the reaction process is complex, and the yield is low; 2) The comparative example 2 contains dibutyl tin oxide (compound 4), which is a highly toxic drug, belongs to a controlled reagent, is unfavorable for industrialization, and has lower synthesis yield because 3' -O-propynyl-uridine isomer can be produced in the synthesis process. Therefore, the application provides a new idea for synthesizing 2' -O-propynyl-uridine, which adopts 2,2' -dehydrated uridine as a substrate and synthesizes 2' -O-propynyl-uridine through a series of reactions, thereby avoiding the generation of isomers, reducing the difficulty of the purification process and lowering the cost.
Although the present disclosure describes embodiments, not every embodiment is described in terms of a single embodiment, and such description is for clarity only, and one skilled in the art will recognize that the embodiments may be combined in any suitable manner to form other embodiments that will be apparent to those skilled in the art.
The above list of detailed descriptions is only specific to practical embodiments of the present invention, and they are not intended to limit the scope of the present invention, and all equivalent embodiments or modifications that do not depart from the spirit of the present invention should be included in the scope of the present invention.

Claims (4)

1. The synthesis method of the medical intermediate 2' -O-propynyl-uridine is characterized by comprising the following steps of:
Adding 2,2 '-dehydrated uridine into a reaction vessel at the temperature of minus 5 ℃ to 5 ℃, continuously introducing inert gas into the reaction vessel, continuously adding an organic solvent and propynyloxy silane into the reaction vessel under the protection of the inert gas in sequence, fully stirring for reaction, slowly dropwise adding boron trifluoride diethyl ether into the reaction vessel at the temperature of minus 5 ℃ to 5 ℃, fully stirring at the temperature of minus 5 ℃ to 5 ℃, heating the reaction vessel to 115 ℃ to 125 ℃, stirring for reaction at the temperature of 115 ℃ to 125 ℃, and sequentially carrying out reduced pressure concentration, column chromatography purification and reduced pressure concentration after the reaction is completed to obtain 2' -O-propynyl-uridine, wherein the propynyloxy silane is tert-butyldimethyl (2-propynyloxy) silane or propynyloxy trimethyl silane;
the molar ratio of the 2,2 '-dehydrated uridine to the tert-butyldimethyl (2-propynyloxy) silane is 1:4-1:6, or the molar ratio of the 2,2' -dehydrated uridine to the propynyloxy trimethyl silane is 1:4-1:6;
The molar volume ratio of the 2,2' -dehydrated uridine to the organic solvent ranges from 0.5mol/L to 1.5mol/L;
the organic solvent is any one of N, N-dimethylacetamide and dimethyl sulfoxide;
The molar ratio of the boron trifluoride diethyl etherate to the 2,2' -dehydrated uridine is 1:2-1:3.
2. The method for synthesizing 2' -O-propynyl-uridine as defined in claim 1, wherein the eluent used for the column chromatography purification is a mixed solution of dichloromethane and methanol, and the mixed solution further contains triethylamine with a volume percentage of 5%.
3. The method for synthesizing 2' -O-propynyl-uridine, which is a pharmaceutical intermediate according to claim 1, wherein the inert gas is any one of nitrogen, neon, helium and argon.
4. The method for synthesizing 2' -O-propynyl-uridine, which is a pharmaceutical intermediate according to claim 1, wherein the reaction progress is controlled by HPLC at a temperature of 115℃to 125 ℃.
CN202410023958.6A 2024-01-08 2024-01-08 Synthesis method of medical intermediate 2' -O-propynyl-uridine Active CN117510562B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410023958.6A CN117510562B (en) 2024-01-08 2024-01-08 Synthesis method of medical intermediate 2' -O-propynyl-uridine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410023958.6A CN117510562B (en) 2024-01-08 2024-01-08 Synthesis method of medical intermediate 2' -O-propynyl-uridine

Publications (2)

Publication Number Publication Date
CN117510562A CN117510562A (en) 2024-02-06
CN117510562B true CN117510562B (en) 2024-04-26

Family

ID=89755461

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410023958.6A Active CN117510562B (en) 2024-01-08 2024-01-08 Synthesis method of medical intermediate 2' -O-propynyl-uridine

Country Status (1)

Country Link
CN (1) CN117510562B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215106A1 (en) * 2020-04-23 2021-10-28 株式会社ダイセル Polyorganosilsesquioxane, multilayer body and surface-coated molded body

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215106A1 (en) * 2020-04-23 2021-10-28 株式会社ダイセル Polyorganosilsesquioxane, multilayer body and surface-coated molded body

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Martin Egli等.Probing the Influence of Stereoelectronic Effects on the Biophysical Properties of Oligonucleotides: Comprehensive Analysis of the RNA Affinity, Nuclease Resistance, and Crystal Structure of Ten 2’-O-Ribonucleic Acid Modifications.《Biochemistry》.2005,第44卷(第25期),全文. *
Martin Egli等.Probing the Influence of Stereoelectronic Effects on the Biophysical Properties of Oligonucleotides: Comprehensive Analysis of the RNA Affinity, Nuclease Resistance, and Crystal Structure of Ten 2’-O-Ribonucleic Acid Modifications.《Biochemistry》.2015,第44卷全文. *
Prediction of the stability of modified RNA duplexes based on deformability analysis: Oligoribonucleotide derivatives modified with 2 ́-O-cyanoethyl-5-propynyl-2-thiouridine as a promising component;Yoshiaki Masaki，等,;《Chemical Communication》;20120607;第48卷(第58期);全文 *
Probing the Influence of Stereoelectronic Effects on the Biophysical Properties of Oligonucleotides: Comprehensive Analysis of the RNA Affinity, Nuclease Resistance, and Crystal Structure of Ten 2’-O-Ribonucleic Acid Modifications;Martin Egli等;《Biochemistry》;20150406;第44卷;全文 *

Also Published As

Publication number Publication date
CN117510562A (en) 2024-02-06

Similar Documents

Publication Publication Date Title
US10167308B2 (en) Highly efficient synthesis of long RNA using reverse direction approach
AU2005328382B2 (en) Oligonucleotides comprising a modified or non-natural nucleobase
JP5714490B2 (en) Methods for preparing oligonucleotides by RNA synthesis, phosphoramidites for synthetic RNA in the reverse direction, and bond formation in the 5 'to 3' direction for synthesis of RNA oligomers
CA2878945A1 (en) Chiral control
Madhuri et al. Design and synthesis of dephosphono DNA analogues containing 1, 2, 3-triazole linker and their UV-melting studies with DNA/RNA
CN117384988B (en) Synthesis method of medical intermediate 2' -O-propynyl-guanosine
CN117510562B (en) Synthesis method of medical intermediate 2' -O-propynyl-uridine
Puffer et al. 2′-Methylseleno-modified oligoribonucleotides for X-ray crystallography synthesized by the ACE RNA solid-phase approach
CN117551155B (en) Synthesis method of 5'-O-DMT-2' -O-propynyl-uridine
Pongracz et al. α-Oligodeoxyribonucleotide N3′→ P5′ phosphoramidates: synthesis and duplex formation
CN108997460A (en) The fluoro- 2`-C- methyluridine phosphoramidite monomer of 2`- deoxidation -2`- and its synthetic method
AU2020292763B2 (en) Process for the preparation of oligonucleotides using modified oxidation protocol
CN108659080A (en) A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method
JP5075340B2 (en) Nucleoside derivatives
CN117417400B (en) Synthesis method of 2 '-O-propynyl-5' -dimethoxytrityl-N4-acetyl-cytidine
CN117510564B (en) Synthesis method of medical intermediate N2-Ac-5'-O-DMT-2' -O-propargyl guanosine
Wiegand et al. A Platform for Controlled Template-Independent Enzymatic Synthesis of RNA Oligonucleotides and Therapeutics
Benckendorff et al. Preparation of a 4′‐Thiouridine Building‐Block for Solid‐Phase Oligonucleotide Synthesis
CN117866026A (en) Medical intermediate and preparation method thereof
Madsen et al. Synthesis, nucleic acid hybridization properties and molecular modelling studies of conformationally restricted 3′-O, 4′-C-methylene-linked α-l-ribonucleotides
Madsen et al. LNA 5′-phosphoramidites for 5′→ 3′-oligonucleotide synthesis
CN117866028A (en) Medical intermediate and preparation method thereof
CN108948103A (en) The fluoro- 2`-C- methyl guanosine phosphoramidite monomer of 2`- deoxidation -2`- and its synthetic method
CN117756873A (en) Method for preparing N-acetylgalactosamine oligonucleotide conjugate based on click chemistry technology
CN117756871A (en) Method for preparing N-acetylgalactosamine oligonucleotide conjugate based on click chemistry technology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant